Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury
Evotec SE (NASDAQ:EVO) has joined the NURTuRE-AKI consortium to study acute kidney injury (AKI) through a comprehensive patient cohort study. The initiative will collect longitudinal data and biological samples from three key patient groups: iatrogenic AKI following cardiac surgery, AKI to chronic kidney disease transition, and pediatric AKI.
The study will integrate with Evotec's Molecular Patient Database (E.MPD), conducting state-of-the-art omics analyses on blood, urine, and research biopsy samples. This collaboration aims to identify novel therapeutic targets and biomarkers for AKI treatment, addressing a significant unmet medical need.
Evotec SE (NASDAQ:EVO) ha aderito al consorzio NURTuRE-AKI per studiare l'insufficienza renale acuta (AKI) attraverso uno studio completo su una coorte di pazienti. L'iniziativa raccoglierà dati longitudinali e campioni biologici da tre gruppi chiave di pazienti: AKI iatrogena dopo interventi cardiaci, la transizione da AKI a malattia renale cronica e AKI pediatrica.
Lo studio sarà integrato con il Database Molecolare del Paziente di Evotec (E.MPD), eseguendo analisi omiche all'avanguardia su campioni di sangue, urine e biopsie di ricerca. Questa collaborazione mira a identificare nuovi bersagli terapeutici e biomarcatori per il trattamento dell'AKI, rispondendo a un bisogno medico significativo ancora insoddisfatto.
Evotec SE (NASDAQ:EVO) se ha unido al consorcio NURTuRE-AKI para estudiar la lesión renal aguda (AKI) mediante un estudio integral de una cohorte de pacientes. La iniciativa recopilará datos longitudinales y muestras biológicas de tres grupos clave de pacientes: AKI iatrogénica tras cirugía cardíaca, transición de AKI a enfermedad renal crónica y AKI pediátrica.
El estudio se integrará con la Base de Datos Molecular de Pacientes de Evotec (E.MPD), realizando análisis ómicos de última generación en muestras de sangre, orina y biopsias de investigación. Esta colaboración tiene como objetivo identificar nuevos objetivos terapéuticos y biomarcadores para el tratamiento de la AKI, abordando una necesidad médica importante aún no satisfecha.
Evotec SE (NASDAQ:EVO)는 급성 신손상(AKI)을 연구하기 위해 NURTuRE-AKI 컨소시엄에 참여했습니다. 이 연구는 세 가지 주요 환자군에서 종단적 데이터와 생물학적 샘플을 수집합니다: 심장 수술 후 유발된 AKI, AKI에서 만성 신장 질환으로의 전환, 소아 AKI.
이 연구는 Evotec의 분자 환자 데이터베이스(E.MPD)와 통합되어 혈액, 소변, 연구용 생검 샘플에 대해 최첨단 오믹스 분석을 수행합니다. 이 협력은 AKI 치료를 위한 새로운 치료 표적과 바이오마커를 발견하여 중요한 미충족 의료 수요를 해결하는 것을 목표로 합니다.
Evotec SE (NASDAQ:EVO) a rejoint le consortium NURTuRE-AKI pour étudier l'insuffisance rénale aiguë (IRA) à travers une étude complète d'une cohorte de patients. L'initiative collectera des données longitudinales et des échantillons biologiques provenant de trois groupes clés de patients : IRA iatrogène après chirurgie cardiaque, transition de l'IRA vers la maladie rénale chronique, et IRA pédiatrique.
L'étude sera intégrée à la Base de Données Moléculaire des Patients d'Evotec (E.MPD), réalisant des analyses omiques de pointe sur des échantillons de sang, d'urine et de biopsies de recherche. Cette collaboration vise à identifier de nouvelles cibles thérapeutiques et biomarqueurs pour le traitement de l'IRA, répondant à un besoin médical important non satisfait.
Evotec SE (NASDAQ:EVO) ist dem NURTuRE-AKI-Konsortium beigetreten, um akutes Nierenversagen (AKI) durch eine umfassende Patienten-Kohortenstudie zu untersuchen. Die Initiative wird longitudinale Daten und biologische Proben von drei Schlüsselpatientengruppen sammeln: iatrogene AKI nach Herzoperation, Übergang von AKI zu chronischer Nierenerkrankung und pädiatrische AKI.
Die Studie wird mit der Molecular Patient Database (E.MPD) von Evotec integriert und führt hochmoderne Omics-Analysen an Blut-, Urin- und Forschungsbiopsieproben durch. Ziel der Zusammenarbeit ist es, neue therapeutische Ziele und Biomarker für die AKI-Behandlung zu identifizieren und damit einen bedeutenden ungedeckten medizinischen Bedarf zu adressieren.
- Integration with Evotec's Molecular Patient Database enhances drug discovery capabilities
- Access to comprehensive patient data and biological samples for targeted drug development
- Potential to develop novel therapeutic targets and biomarkers for AKI treatment
- Partnership with established research consortium led by Kidney Research UK
- None.
Insights
Evotec's partnership with NURTuRE-AKI strengthens their kidney disease R&D platform, potentially creating long-term drug development opportunities.
Evotec's strategic move to join the NURTuRE-AKI consortium represents a significant enhancement to their multi-omics research capabilities in kidney disease. The partnership gives Evotec access to a comprehensive longitudinal patient cohort with biological samples and detailed clinical data from acute kidney injury (AKI) patients, including three clearly defined groups: post-cardiac surgery AKI, AKI-to-CKD transition, and pediatric AKI.
This collaboration directly strengthens Evotec's Molecular Patient Database (E.MPD), their repository of multi-omics data and clinical records. The value proposition lies in the potential to identify novel therapeutic targets and biomarkers through molecular-level understanding of AKI, a condition with significant unmet medical need.
From a drug discovery perspective, this partnership may accelerate Evotec's pipeline development in nephrology. By gaining access to high-quality patient samples with longitudinal data points, Evotec can potentially identify disease mechanisms and drug targets that might otherwise remain undiscovered through traditional research approaches.
While this announcement doesn't represent an immediate revenue opportunity, it strengthens Evotec's position as a leading drug discovery platform in kidney disease. The company is actively seeking additional partners to maximize the value of this initiative, suggesting potential for future collaborative arrangements that could generate revenue through research partnerships or out-licensing opportunities.
NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UK
The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chronic kidney disease ("CKD") transition and pediatric AKI.
This partnership will enable Evotec to understand human disease progression on a molecular level and to perform targeted drug discovery in the field of AKI.
HAMBURG, DE / ACCESS Newswire / June 25, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it has joined the NURTuRE-AKI consortium for establishing a patient cohort for acute kidney injury (AKI), NURTuRE-AKI. This initiative will enable Evotec to identify key mechanisms that trigger AKI and to support the discovery of highly innovative treatments for AKI patients based on a molecular understanding of the disease.
NURTuRE-AKI focuses on adult and pediatric cardiac surgery patients who are at high risk of developing AKI as well as patients undergoing AKI-to-CKD progression. The longitudinal study design includes biological sampling and clinical data collection at multiple time points for each patient. Blood, urine and research biopsy samples will be subjected to state-of-the-art omics analyses, forming the most comprehensive patient cohort for AKI and AKI-to-CKD worldwide.
NURTuRE-AKI will be integral to Evotec's Molecular Patient Database (E.MPD), a repository of high-quality multi-omics data (PanOmics) and detailed clinical records. This new addition will further enhance Evotec's understanding of human diseases and expand its capabilities in precision medicine, drug discovery and development programs.
"NURTuRE-AKI will unlock the identification of novel therapeutic targets and biomarkers based on comprehensive molecular and clinical patient data. This will accelerate the development of targeted therapies for a disease with a high unmet medical need, providing immense benefits for millions of patients worldwide", said Dr Cord Dohrmann, Chief Scientific Officer of Evotec . "We are extremely thrilled to be a vital part of this unique venture, which marks a significant step for Evotec in expanding its leadership in kidney disease drug discovery. To fully realize the potential of this initiative, we are actively seeking partners who share our commitment to transforming kidney disease treatment."
"Kidney Research UK are delighted to be partnering with Evotec and our other collaborators to develop NURTuRE-AKI, which will form a crucial resource for future research and innovation. We are already seeing important new findings from the initial NURTuRE CKD and INS cohorts and are confident that this venture has similarly great potential to change diagnosis and care for kidney disease patients." Elaine Davies, Director of research operation Kidney Research UK .
About Acute Kidney Injury
AKI is a sudden decline in kidney function, associated with an increased risk of mortality and a leading cause of chronic kidney disease (CKD). Major causes of AKI include alterations in blood pressure and the use of contrast agents for angiography, occurring during cardiac surgeries. Currently, there are no preventive or therapeutic treatments for AKI.
About Kidney Research UK
Kidney Research UK is the leading charity dedicated to funding research into the prevention, treatment and management of kidney disease. Led by the patient voice, we have spent over 60 years working with clinicians, scientists and partners across sectors to drive innovation and improve lives - investing
Find out more at www.kidneyresearchuk.org .
About NURTuREand NURTuRE-AKI
NURTuRE is a unique resource for the kidney disease community, accelerating discovery of new treatments and diagnostic approaches through secure provision of a rich resource of biological samples and data. The initial cohorts comprised 3,000 individuals with CKD and 740 with idiopathic nephrotic syndrome (INS).
With the development of NURTuRE-AKI, this resource will be extended to include samples and data from AKI patients included in three sub cohorts. The first sub cohort comprises 400 adult individuals undergoing cardiac surgery with cardiopulmonary bypass. The risk of AKI incidence in this setting is approximately
The study will run over a three-year period, the samples will be obtained through 13 NHS Trusts, with patients followed up at specific intervals.
In addition to the samples of plasma, serum, urine, DNA and tissue, NURTuRE-AKIwill also have the considerable advantage of containing associated linked clinical data, through the UK Renal Registry.
NURTuRE-AKI is funded by Evotec, AstraZeneca, Nephrolyx and Kidney Research UK. Experts from the Leeds Teaching Hospital NHS Trust, University of Bristol and University Hospital Birmingham form the core academic team overseeing all operational delivery.
More information is available here: www.nurturebiobank.org .
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision.
Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.
With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.
Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.
With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.
Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Media
Susanne Kreuter
VP Head of Strategic Marketing
Susanne.Kreuter@evotec.com
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire
FAQ
What is the purpose of Evotec (NASDAQ:EVO) joining the NURTuRE-AKI consortium?
Which patient groups will be studied in the NURTuRE-AKI research?
How will the NURTuRE-AKI study collect patient data?
How will this partnership benefit Evotec's drug discovery capabilities?
What is the potential impact of the NURTuRE-AKI study on kidney disease treatment?
